Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab

NCT01338740 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT01338740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01338740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Lead sponsor
University Hospital, Ghent
Phase
Observational
Overall status
Completed
Start date
April 30, 2011
Completion date
February 17, 2014
Enrollment
21 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease